GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Loans Receivable

Scandion Oncology A/S (OSTO:SCOL) Loans Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Loans Receivable?

Scandion Oncology A/S's Loans Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Scandion Oncology A/S Loans Receivable Historical Data

The historical data trend for Scandion Oncology A/S's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S Loans Receivable Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Scandion Oncology A/S Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Scandion Oncology A/S Loans Receivable Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines